Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.

BMC cancer - 27 Apr 2018

Mei Zhu, Shao Yang W, Lin Peinan, Cai Xiaomin, Wang Biao, Ding Yan, Ma Xiangyuan, Wu Xue, Xia Yewei, Zhu Dongqin, Shu Yongqian, Fu Zan, Gu Yanhong

Abstract excerpt

BACKGROUND: Cetuximab, an anti-EGFR monoclonal antibody, is used in combination with chemotherapy in clinic to enhance the outcome in metastatic colorectal cancer (mCRC) patients with only ~ 20% response rate. To date only activating mutations in KRAS and NRAS have been identified as poor prognosis biomarkers in cetuximab-based treatment, which makes an urgent need for identification of novel prognosis biomarkers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Neurofibromin 1

Share to Proto-Oncogene Proteins p21(ras)

Share to Smad4 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 29703253
DOI: 10.1186/s12885-018-4298-5
PMCID: PMC5921972

Genes

SMAD4
EGFR
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.PMID 29703253Read ↗

Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysisSemantic proximity Read ↗

Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.Semantic proximity Read ↗

SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.Semantic proximity Read ↗

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.Semantic proximity Read ↗

Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.Semantic proximity Read ↗

NF1 germline mutation in a Chinese family with colon cancer.Semantic proximity Read ↗

Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal Cancer.Semantic proximity Read ↗

Is there any correlation among MKK4 (mitogen-activated protein kinase kinase 4) expression, clinicopathological features, and KRAS/NRAS mutation in colorectal cancer.Semantic proximity Read ↗

SMAD4 Somatic Mutations in Head and Neck Carcinoma Are Associated With Tumor ProgressionSemantic proximity Read ↗

Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.Semantic proximity Read ↗

NRXN1 as a Prognostic Biomarker: Linking Copy Number Variation to EMT and Survival in Colon CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.